Effect of tislelizumab combined with albumin bound paclitaxel and tegafur in the second line treatment of advanced gastric cancer
Objective To investigate the effect of tislelizumab combined with albumin bound paclitaxel and tegafur in the second line treatment of advanced gastric cancer.Methods A total of 100 patients with advanced gastric cancer admitted in the oncology department of Baoji Chencang Hospital from January 2020 to January 2023 were selected and randomly divided into control group and observation group,with 50 cases in each group.The control group was treated with albumin bound paclitaxel and tegafur in the second line treatment,and the observation group was treated with tislelizumab on the basis of the control group.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).After treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 72-4(CA72-4)and carbohydrate antigen 199(CA199)in the observation group were lower than those in the control group(P<0.05).After treatment,CD4+and CD4+/CD8+in the observation group were higher than those in the control group,and CD8+was lower than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Tislelizumab combined with albumin bound paclitaxel and tegafur in the second line treatment of patients with advanced gastric cancer is helpful to improve the therapeutic effect,reduce the levels of tumor markers,and improve immune function,which is worthy of promotion.
tislelizumabalbumin bound paclitaxeltegafurgastric cancer
NETL
NSTL
万方数据
